DJI Launches All-in-One Vlog Camera Drone with DJI Flip

New DJI Flip is DJI's first drone to feature foldable, full-coverage propeller guards for ultimate flight safety

SHENZHEN, China, Jan. 14, 2025 /PRNewswire/ -- DJI, the global leader in civilian drones and creative camera technology, today announces DJI Flip, a new series of all-in-one vlog camera drones. At less than 249g^[1], this compact drone features foldable full-coverage propeller guards^[1], ensuring ultra-safe and reliable flying. Photographers can capture impressive 48MP photos and 4K videos with the drone's 1/1.3-inch CMOS sensor with one tap of a button. Being fully equipped with comprehensive protection at all times, even beginner pilots can confidently navigate the skies with DJI Flip.

"Building on the success of our consumer camera drones, we are introducing DJI Flip to combine the simplicity of the DJI Neo with the stunning photo capabilities of the DJI Mini to make both aerial photography and close-up portraits accessible for everyone," said Ferdinand Wolf, Product Experience Director at DJI. "DJI Flip combines creative tools like AI subject tracking^[1] and intelligent shooting modes^[1] with safety features like our latest foldable propeller guards and automatic braking, making it easier than ever for people to capture stunning aerial footage no matter their level of photography or drone expertise."

Ultra Safe and Reliable Flights

DJI Flip makes flying safe and reliable thanks to its foldable, full-coverage guard that wraps the propellers to avoid injury or damage to the drone. Made of lightweight and strong carbon fiber string, the guard's support structure is only 1/60 the weight of guards made with traditional polycarbonate material while maintaining the same stiffness and durability to ensure safe flights.

Intelligent One-Tap Aerial Photography

DJI Flip makes flying simple, requiring no special training in most countries and regions. This palm-sized drone is lightweight and compact, making it an ideal travel companion for capturing any adventure. Whether hiking through forests or climbing steep peaks, DJI Flip makes flying simple. With one tap of the mode button, photographers can select from six intelligent shooting modes to capture impressive footage. AI Subject Tracking^[1] can also be enabled to keep a subject in the frame. Six intelligent shooting modes include Dronie, Circle, Rocket, Spotlight, Helix, and Boomerang.  

Strong Camera with Smart Enhancements 

DJI Flip can capture high-dynamic 48MP photos with more highlight and shadow details. The camera is powered by a 1/1.3-inch CMOS sensor featuring Dual Native ISO Fusion, f/1.7 aperture, and 2.4μm 4-in-1 pixels. It can also capture photos with up to 4x zoom. Intricate details can be preserved with next-gen SmartPhoto^[1], which combines HDR imaging, scene recognition, and more for images that pop. 

DJI Flip records HDR video at 4K resolution and 60 frames per second, promising footage with true-to-life quality. It also supports slow-motion recording at 4K/100fps and 10-bit D-Log M color mode. A 4:3-aspect-ratio CMOS sensor provides enough space for vertical crops while maintaining a 2.7k resolution, optimized for smartphone viewing and social media without any cropping needed.

DJI's intelligent shooting features easily produce professional-grade work:

• MasterShots: Allows DJI Flip to automatically perform diverse camera movements, shooting multiple clips and editing them with music, cuts, and effects for fast and simplified cinematic footage.
• Hyperlapse: Select from four options, including Free, Circle, Course Lock, and Waypoint to capture timelapse footage at up to 4K horizontally or 2.7K vertically.
• FocusTrack: Find creative ways to follow your subject with FocusTrack. The suite includes ActiveTrack 4.0, Spotlight 2.0, and Point of Interest 3.0, three powerful storytelling tools.
• Panorama: Supports shooting 180°, Wide Angle, Vertical, and Sphere panoramic photos to capture magnificent landscapes.

Other Standout Features

• 31-minute Max Flight Time^[1]: DJI Flip's Intelligent Flight Battery delivers up to 31 minutes of flight time, ensuring seamless creation without battery concerns.
• Automatic Braking^[1]: DJI Flip's 3D Infrared Sensing System support automatic braking for enhanced safety, even at night.
• Next Level Video Transmission: When paired with the DJI RC-N3 or RC 2 remote controller, DJI O4 video transmission supports up to 13 km^[1] of 1080p/60fps video transmission and has excellent anti-interference capabilities, allowing you to explore vast landscapes with clarity.
• Fast Charging and Data Transfers^[1]: The DJI Flip Parallel Charging Hub charges two batteries simultaneously^[1], significantly reducing charging time. With the DJI Fly app, footage can be transferred at speeds up to 30MB/s.
• Fly With or Without Remote Controller: The DJI Flip can be operated with the DJI RC-N3 or RC 2 remote controllers. It can also operate with the DJI Fly app or Voice Control^[1] for hands-free flying. When connected to your phone, it can capture audio and intelligently reduce noise, automatically filtering out propeller noise

Price and Availability

DJI Flip is available to order from store.dji.com and authorized retail partners, with shipping starting today, in the following configurations:

• DJI Flip retails for $439
• DJI Flip (DJI RC 2) retails for $639
• DJI Flip Fly More Combo (DJI RC 2) retails for $779

DJI Care Refresh

DJI Care Refresh, the comprehensive protection plan for DJI products, is now available for DJI Flip. The replacement service covers accidental damage, including flyaway, collisions and water damage. For a small additional charge, you can have your damaged product replaced if an accident occurs.

DJI Care Refresh (1-Year Plan) includes up to two replacements in one year. DJI Care Refresh (2-Year Plan) includes up to four replacements in two years. Other services of DJI Care Refresh include official Warranty and free shipping. For a full list of details, please visit: https://www.dji.com/support/service/djicare-refresh. 

For more information, please refer to https://www.dji.com/flip.

^[1] All data was tested in controlled conditions. Actual experience may vary. For more details, please refer to the product page on the official DJI website.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

DJI Launches All-in-One Vlog Camera Drone with DJI Flip

HIGHLIGHTS

• Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol.

Patient population

• With the SECuRE trial continuing to recruit, a total of nine participants who had evaluable data by the 25^th of November 2025 were included in the interim assessment by the SRC, with the majority of participants receiving at least two cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each by the data cut-off date.
• Seven participants received ⁶⁷Cu-SAR-bisPSMA and two participants were treated with a combination of ⁶⁷Cu-SAR-bisPSMA with enzalutamide.
• Most participants were heavily pre-treated (with 55.6% having received more than 5 previous anti-cancer regimens) and had bone metastasis (66.7%).

Safety

• The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable with most related adverse events (AEs) in the Cohort Expansion to date being Grade 1 or 2. The most common AEs were nausea and lymphopenia (observed in 33.3% of participants, for each AE).

Efficacy

• Six participants had at least two prostate specific antigen (PSA) results following ⁶⁷Cu-SAR-bisPSMA administration, with all showing a decrease in PSA. Of those, four participants (66.7%) thus far had a reduction of more than 50% in PSA (PSA50) and two participants (33.3%) had a reduction of more than 80% (PSA80).
• One participant who presented with bone metastasis at enrolment achieved undetectable PSA with no prostate cancer detected by computed tomography (CT) or bone scan following ⁶⁷Cu-SAR-bisPSMA treatment. The participant reported having excellent quality of life following the treatment.

Next Steps

• The SECuRE trial will continue enrolment into the Cohort Expansion Phase with planned completion of recruitment in 2026. Phase III registrational trial planning ongoing based on data generated to date.

SYDNEY, Jan. 15, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to share a number of updates on the SECuRE trial following an SRC meeting. The SRC has recommended that the trial continue with the Cohort Expansion Phase (Phase II) as planned with no modifications to the protocol. The interim results assessed by the SRC were collected from nine participants enrolled in the cohort that had evaluable data by the cut-off date of the 25^th of November 2025 and continue to show promising efficacy and a favourable safety profile of ⁶⁷Cu-SAR-bisPSMA.

The majority of the nine participants had bone metastasis at enrolment (66.7%) and received multiple lines of previous treatments (more than 5 previous anti-cancer regimens, 55.6%). Median PSA prior to ⁶⁷Cu-SAR-bisPSMA treatment was 18.9 ng/mL (range 1.5-30.2 ng/mL). Six out of these nine participants received at least 2 cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each, with two of them also receiving concomitant enzalutamide.

Of the nine participants included in this SRC analysis, six had at least two PSA results following their ⁶⁷Cu-SAR-bisPSMA treatment by the data cut-off date. Of these six participants, thus far four (66.7%) showed reductions in PSA of 50% or more (PSA50) and two (33.3%) showed reductions of 80% or more (PSA80).

The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable in the Cohort Expansion, with the majority of related AEs being Grade 1 or 2. The most common related AEs were nausea and lymphopenia (observed in three out of nine participants [33.3%], for each AE). The only AE that was Grade 3 or above was lymphopenia observed in three participants, some of whom had bone metastasis at baseline and/or had received multiple lines of therapy, including taxane and an investigational agent, prior to enrolment in the SECuRE study. There have been no overall renal toxicity or electrocardiogram (ECG) changes observed in these participants. In the combination enzalutamide arm, no new AEs (or worsening of AEs) related to ⁶⁷Cu-SAR-bisPSMA have been observed to date.

Trial participant with no detectable disease after 3 cycles of ⁶⁷Cu-SAR-bisPSMA

One of the participants in the Cohort Expansion was a 64-year-old man with bone metastases and baseline PSA of 5.4 ng/mL prior to entering the SECuRE study. Following his first cycle of ⁶⁷Cu-SAR-bisPSMA, this participant showed a dramatic 95.2% reduction in PSA. He went on to receive 2 more cycles of ⁶⁷Cu-SAR-bisPSMA and achieved undetectable PSA levels. In a follow-up bone scan and CT no metastatic disease was observed. This participant only exhibited mild (Grade 1) related AEs, most of which were gastrointestinal events, with no haematological or renal AEs observed. The participant reported having excellent quality of life following the treatment.

The interim data from this Phase II continues to confirm the favourable safety profile and promising efficacy seen in previous cohorts of the SECuRE trial^[1] and supports the continuation of the trial with the aim to progress to a registrational Phase III study.

Clarity's Executive Chairperson, Dr Alan Taylor, commented, "SAR-bisPSMA continues generating world-class data in both theranostic and diagnostic trials. The combination of the optimised dimer 'bis' structure with the benefits of copper isotopes, enabled by the proprietary sarcophagine technology, is proving to have created a product that is here to challenge the current treatment and diagnostic paradigms in radiopharmaceuticals.

"We have already seen a glimpse of the effects of ⁶⁷Cu-SAR-bisPSMA through our Dose Escalation cohorts with additional and similar data being generated in the Cohort Expansion phase, demonstrating once again excellent efficacy and safety results of ⁶⁷Cu-SAR-bisPSMA.

"All of the participants with evaluable data treated in the Phase II to date have shown declines in PSA, with the majority showing PSA decreases of more than 50% and mostly having only mild or moderate AEs. Most of these patients have been treated with more than 5 systemic treatment regiments and had bone metastasis prior to entering the SECuRE study. Although the number of participants with evaluable data to date is small, it is incredible to see yet another extraordinary case where a patient who had bone metastasis prior to entering the study achieved undetectable PSA following ⁶⁷Cu-SAR-bisPSMA treatment, with no disease observed by anatomical and molecular imaging at the last assessments. This participant only experienced mild, transient AEs, most being gastrointestinal, and has reported having excellent quality of life following the treatment.

"Importantly, the work we have undertaken during the Dose Escalation Phase is now continuing to provide a strong foundation for us as we look ahead at protocol development and dosing for our Phase III clinical trial and commercialisation. As the participant numbers continue to increase with the trial enrollment, we continue to see very promising responses over and over again, giving us more confidence about the future of this product and its potential for commercialisation in metastatic castration-resistant prostate cancer (mCRPC). With three Fast Track Designations for the SAR-bisPSMA product and positive interactions with the US Food and Drug Administration (FDA) to date, we are working towards bringing this agent to clinicians and their patients around the world through the entirety of the prostate cancer journey, from first diagnosis to late-stage disease. All of these indications, being imaging in pre-definitive therapy and biochemical recurrence, as well as therapy in mCRPC, are blockbuster markets individually for prostate-specific membrane antigen (PSMA) targeted products, with an estimated combined market value of approximately US$10-15 billion by 2030. We are committed to continuing the development of this product, aiming to bring improved diagnostic and treatment options for prostate cancer in various stages of their disease."

About the SECuRE trial

The SECuRE trial (NCT04868604)^[2] is a Phase I/IIa theranostic trial for identification and treatment of participants with PSMA-expressing mCRPC using ⁶⁴Cu/⁶⁷Cu-SAR-bisPSMA. ⁶⁴Cu-SAR-bisPSMA is used to visualise PSMA-expressing lesions and select candidates for subsequent ⁶⁷Cu-SAR-bisPSMA therapy. The trial is a multi-centre, single arm, dose escalation study with a cohort expansion involving approximately 54 participants in the US. The overall aim of the trial is to determine the safety and efficacy of ⁶⁷Cu-SAR-bisPSMA for the treatment of prostate cancer.

The SECuRE trial consists of the Dose Escalation (Phase I) and Cohort Expansion (Phase II) Phases. Based on the data from the Dose Escalation Phase, which demonstrated a favourable safety profile and efficacy of ⁶⁷Cu-SAR-bisPSMA, the SECuRE trial progressed to the Cohort Expansion (Phase II) at an 8 GBq dose level as per the SRC recommendation (up to 6 cycles per patient in total)^[3].

Cohort 2 of the Dose Escalation phase of the trial, where participants were dosed with 8 GBq of ⁶⁷Cu-SAR-bisPSMA, demonstrated a very low rate of related AEs while all three participants achieved PSA declines of 80% or more (PSA80)^[1]. The Dose Escalation Phase also showed high PSA response rates of the mCRPC in the pre-chemotherapy setting with a favourable safety profile: 92% of pre-chemotherapy participants (12/13) demonstrated PSA drops greater than 35%, PSA reductions greater than 50% were reached in 61.5% (8/13) of participants, and reductions of 80% or more were achieved in 46.2% (6/13) of participants^[1]. These results supported the progress of the trial to its Cohort Expansion Phase using 8 GBq multi-dose in participants who had not received chemotherapy in the mCRPC setting.

Recruitment is currently ongoing into the Cohort Expansion Phase which will include 24 participants. A subset of participants will be treated with the combination of 8 GBq of ⁶⁷Cu-SAR-bisPSMA with enzalutamide (androgen receptor pathway inhibitor [ARPI]), in line with the positive results from the Enza-p trial^[4] and previous discussions with and advice from key global medical experts in the field of prostate cancer, including the Company's Clinical Advisory Board members, Prof Louise Emmett and Prof Oliver Sartor, as well as the SRC.

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity's proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy.

⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of ⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide^[5]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease^[6].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact: